Mediastinal Neoplasms
6
0
0
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
33.3%
2 terminated out of 6 trials
33.3%
-53.2% vs benchmark
33%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions
22G-Adapt Needle Biopsy Versus Fine-needle Aspiration in Endoscopic Ultrasound-guided Sampling of Solid Lesions
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer